Recursion Pharmaceuticals, Inc. RXRX
5 trading plans running, 63 Form 144 notices for $18.1M
10-Q, 10-K and Form 144What RXRX's directors and officers said they would sell, before they sold: trading plans the company reports each quarter, and the Form 144 notices sellers file on the day of a planned sale. Most of these sales are routine, such as selling shares from vesting stock awards.
Plans adopted or ended
Trading plans · XBRL, 10-Q and 10-K
From Dec 27, 2023 to Jun 2, 2027. The thin line is today; a filled bar is a plan still running, a paler one has ended or expired. The ten newest plans are drawn; all are in the table.
| Insider | What | Date | Reported in | ||
|---|---|---|---|---|---|
| Namandjé Bumpus a member of our Board of Directors |
Adopted 10b5-1 plan | Mar 3, 2026 | 10-Q May 6, 2026 | ||
What the company wroteOn March 3, 2026, Namandjé Bumpus, a member of our Board of Directors, adopted a Rule 10b5-1 trading arrangement that is intended to satisfy the affirmative defense of Rule 10b5-1(c) for the potential sale of up to 12,735 shares of the Company’s Class A common stock until June 2, 2027 . | |||||
| Robert Hershberg Vice Chair and Lead Independent Director |
Adopted 10b5-1 plan | Dec 18, 2025 | 10-K Feb 25, 2026 | ||
What the company wroteOn December 18, 2025, Robert Hershberg, Vice Chair and Lead Independent Director, adopted a Rule 10b5-1 trading arrangement that is intended to satisfy the affirmative defense of Rule 10b5-1(c) for the sale of up to 525,000 shares of the Company’s Class A common stock, a majority of which will not execute absent a significant increase in the market price of the Company’s Class A common stock. The plan is effective until March 19, 2027. | |||||
| Ben Taylor Chief Financial Officer and President of Recursion UK |
Adopted 10b5-1 plan | Sep 30, 2025 | 10-Q Nov 5, 2025 | ||
What the company wroteOn September 30, 2025, Ben Taylor, Chief Financial Officer and President of Recursion UK, adopted a Rule 10b5-1 trading arrangement that is intended to satisfy the affirmative defense of Rule 10b5-1(c) for the sale of up to 293,321 shares of the Company’s Class A common stock until December 29, 2026. | |||||
| Najat Khan Chief R&D Officer, Chief Commercial Officer, and a member of our Board of Directors |
Adopted 10b5-1 plan | Sep 22, 2025 | 10-Q Nov 5, 2025 | ||
What the company wroteOn September 22, 2025, Najat Khan, Chief R&D Officer, Chief Commercial Officer, and a member of our Board of Directors, adopted a Rule 10b5-1 trading arrangement that is intended to satisfy the affirmative defense of Rule 10b5-1(c) for the sale of up to 299,317 shares of the Company’s Class A common stock until December 22, 2026. | |||||
| Blake Borgeson a member of our Board of Directors |
Adopted 10b5-1 plan | Aug 31, 2025 | 10-Q Nov 5, 2025 | ||
What the company wroteOn August 31, 2025, Blake Borgeson, a member of our Board of Directors, adopted a Rule 10b5-1 trading arrangement that is intended to satisfy the affirmative defense of Rule 10b5-1(c) for the potential sale of up to 3,868,000 shares of the Company’s Class A common stock, a majority of which will not execute absent a significant increase in the market price of the Company’s Class A common stock. The plan is effective until no later than December 01, 2026 . | |||||
| Christopher Gibson CEO and President |
Ended 10b5-1 plan | May 12, 2025 | 10-Q Aug 5, 2025 | ||
What the company wroteOn May 12, 2025, Christopher Gibson, CEO and President, and a member of our Board of Directors, terminated (within the meaning of Rule 10b5-1(c)(1)(iv)) a Rule 10b5-1 trading arrangement previously adopted in December 2024, and adopted a subsequent Rule 10b5-1 trading arrangement that is intended to satisfy the affirmative defense of Rule 10b5-1(c) for the sale of up to 86,634 shares of the Company’s Class A common stock and the potential conversion and sale of up to 4,247,433 shares of the Company’s Class B common stock, a majority of which will not execute absent a significant increase in the market price of the Company’s Class A common stock. The plan is effective until no later than August 13, 2026. | |||||
| Christopher Gibson Chief Executive Officer, President, and a member of our Board of Directors |
Adopted 10b5-1 plan | Dec 19, 2024 | 10-K Feb 28, 2025 | ||
What the company wroteOn December 19, 2024, Christopher Gibson, Chief Executive Officer, President, and a member of our Board of Directors, adopted a Rule 10b5-1 trading arrangement that is intended to satisfy the affirmative defense of Rule 10b5-1(c) for the sale of up to 2,343,000 shares of the Company’s Class A common stock until April 9, 2026. | |||||
| Michael Secora Chief Financial Officer |
Adopted 10b5-1 plan | Mar 1, 2024 | 10-Q May 9, 2024 | ||
What the company wroteOn March 1, 2024, Michael Secora, Chief Financial Officer, adopted a Rule 10b5-1 trading arrangement that is intended to satisfy the affirmative defense of Rule 10b5-1(c) for the sale of up to 1,259,955 shares of the Company’s Class A common stock until June 10, 2025. | |||||
| Terry-Ann Burrell member of our Board of Directors |
Adopted 10b5-1 plan | Mar 1, 2024 | 10-Q May 9, 2024 | ||
What the company wroteOn March 1, 2024, Terry-Ann Burrell, a member of our Board of Directors, adopted a Rule 10b5-1 trading arrangement that is intended to satisfy the affirmative defense of Rule 10b5-1(c) for the sale of up to 211,290 shares of the Company’s Class A common stock until May 30, 2025. | |||||
| Tina Marriott President and Chief Operating Officer |
Adopted 10b5-1 plan | Mar 1, 2024 | 10-Q May 9, 2024 | ||
What the company wroteOn March 1, 2024, Tina Marriott, President and Chief Operating Officer, adopted a Rule 10b5-1 trading arrangement that is intended to satisfy the affirmative defense of Rule 10b5-1(c) for the sale of up to 672,000 shares of the Company’s Class A common stock until June 27, 2025. | |||||
| Christopher Gibson Chief Executive Officer and a member of our Board of Directors |
Adopted 10b5-1 plan | Dec 27, 2023 | 10-K Feb 29, 2024 | ||
What the company wroteOn December 27, 2023, Christopher Gibson, Chief Executive Officer and a member of our Board of Directors, adopted a Rule 10b5-1 trading arrangement that is intended to satisfy the affirmative defense of Rule 10b5-1(c) for the sale of up to 620,015 shares of the Company’s Class A common stock until March 6, 2025. | |||||
| Dean Li, member of the Board of Directors |
Adopted 10b5-1 plan | Aug 24, 2023 | 10-Q Nov 9, 2023 | ||
What the company wroteOn August 24, 2023, Dean Li, a member of the Board of Directors, and his affiliates, adopted a Rule 10b5-1 trading arrangement that is intended to satisfy the affirmative defense of Rule 10b5-1(c) for the sale of up to 155,500 shares of the Company’s Class A common stock until November 20, 2024. | |||||
| Blake Borgeson member of our Board of Directors |
Adopted 10b5-1 plan | Aug 18, 2023 | 10-Q Nov 9, 2023 | ||
What the company wroteOn August 18, 2023, Blake Borgeson, a member of our Board of Directors, adopted a Rule 10b5-1 trading arrangement that is intended to satisfy the affirmative defense of Rule 10b5-1(c) for the sale of up to 745,186 shares of the Company’s Class A common stock until November 12, 2024. | |||||
| Zavain Dar member of our Board of Directors |
Adopted 10b5-1 plan | Jun 21, 2023 | 10-Q Aug 8, 2023 | ||
What the company wroteOn June 21, 2023, Zavain Dar, a member of our Board of Directors, adopted a Rule 10b5-1 trading arrangement that is intended to satisfy the affirmative defense of Rule 10b5-1(c) for the sale of up to 20,141 shares of the Company’s Class A common stock until June 21, 2024. | |||||
Show the other 6 plans
From the XBRL of the company's 10-Qs and 10-Ks (Regulation S-K Item 408, reported since 2023): 15 filings checked since May 8, 2023.
Notices of planned sales
Form 144 · Form 144 XML, SEC
What the sellers expected to sell on the Form 144 notices filed each month (the value on the notice).
| Filed | Seller | Shares | Value |
|---|---|---|---|
| Nov 3, 2026 | Borgeson Blake Director |
40,000 | $155K |
| Oct 6, 2026 | Borgeson Blake Director |
50,000 | $242K |
| Oct 6, 2026 | HERSHBERG ROBERT Director |
25,000 | $125K |
| Sep 8, 2026 | Najat Khan Officer |
22,408 | $79K |
| Sep 1, 2026 | Borgeson Blake Director |
30,000 | $100K |
| Aug 21, 2026 | Gibson Christopher Former Director |
77,290 | $262K |
| Aug 20, 2026 | Gibson Christopher Former Director |
75,000 | $255K |
| Aug 19, 2026 | Gibson Christopher Former Director |
100,000 | $328K |
| Aug 18, 2026 | Gibson Christopher Former Director |
26,806 | $80K |
| Aug 13, 2026 | Gibson Christopher Former Director |
100,000 | $331K |
| Aug 12, 2026 | Gibson Christopher Former Director |
50,000 | $168K |
| Aug 10, 2026 | Gibson Christopher Former Director |
100,000 | $327K |
| Aug 7, 2026 | Gibson Christopher Former Director |
100,000 | $325K |
| Aug 4, 2026 | Borgeson Blake Director |
30,000 | $98K |
| Aug 4, 2026 | Gibson Christopher Former Director |
75,000 | $245K |
| Jul 30, 2026 | Gibson Christopher Former Director |
75,000 | $225K |
| Jul 29, 2026 | Gibson Christopher Former Director |
50,000 | $151K |
| Jul 27, 2026 | Gibson Christopher Former Director |
50,000 | $153K |
| Jul 21, 2026 | Gibson Christopher Former Director |
100,000 | $304K |
| Jul 20, 2026 | Gibson Christopher Former Director |
100,000 | $290K |
| Jul 17, 2026 | Gibson Christopher Former Director |
100,000 | $297K |
| Jul 16, 2026 | Gibson Christopher Former Director |
100,000 | $311K |
| Jul 15, 2026 | Gibson Christopher Former Director |
123,334 | $410K |
| Jul 14, 2026 | Gibson Christopher Former Director |
100,000 | $330K |
| Jul 13, 2026 | Gibson Christopher Former Director |
100,000 | $343K |
| Jul 10, 2026 | Gibson Christopher Former Director |
100,000 | $354K |
| Jul 9, 2026 | Gibson Christopher Former Director |
286,000 | $1.1M |
| Jul 8, 2026 | Gibson Christopher Former Director |
200,000 | $738K |
| Jul 7, 2026 | Gibson Christopher Former Director |
250,000 | $988K |
| Jul 7, 2026 | Borgeson Blake Director |
40,000 | $158K |
| Jul 6, 2026 | Gibson Christopher Former Director |
100,000 | $378K |
| Jul 2, 2026 | Gibson Christopher Former Director |
100,000 | $374K |
| Jul 1, 2026 | Gibson Christopher Former Director |
100,000 | $367K |
| Jun 18, 2026 | Gibson Christopher Director |
300,440 | $962K |
| Jun 18, 2026 | Bumpus Namandje Director |
3,963 | $13K |
| Jun 18, 2026 | Gibson Christopher Director |
40,000 | $127K |
| Jun 5, 2026 | Gibson Christopher Director |
40,000 | $145K |
| Jun 5, 2026 | Najat Khan Officer |
23,588 | $84K |
| Jun 3, 2026 | Bumpus Namandje Director |
4,386 | $16K |
| Jun 2, 2026 | Borgeson Blake Director |
30,000 | $110K |
| May 22, 2026 | Gibson Christopher Director |
40,000 | $123K |
| May 7, 2026 | Gibson Christopher Director |
40,000 | $135K |
| May 5, 2026 | Borgeson Blake Director |
30,000 | $106K |
| Apr 22, 2026 | Gibson Christopher Director |
40,000 | $144K |
| Apr 7, 2026 | Gibson Christopher Director |
40,000 | $124K |
| Apr 7, 2026 | Borgeson Blake Director |
30,000 | $93K |
| Mar 23, 2026 | Gibson Christopher Director |
40,000 | $130K |
| Mar 17, 2026 | Taylor Ben R Officer |
7,956 | $27K |
| Mar 9, 2026 | Najat Khan Officer |
28,298 | $95K |
| Mar 3, 2026 | Borgeson Blake Director |
170,000 | $588K |
| Feb 19, 2026 | Gibson Christopher Director |
40,000 | $138K |
| Feb 18, 2026 | Taylor Ben R Officer |
13,426 | $41K |
| Feb 4, 2026 | Gibson Christopher Director |
40,000 | $165K |
| Feb 3, 2026 | Borgeson Blake Director |
220,000 | $924K |
| Jan 20, 2026 | Gibson Christopher Director |
40,000 | $179K |
| Jan 6, 2026 | Borgeson Blake Director |
220,000 | $959K |
| Jan 5, 2026 | Gibson Christopher Director |
40,000 | $170K |
| Dec 29, 2025 | Taylor Ben R Officer |
21,383 | $89K |
| Dec 22, 2025 | Najat Khan Officer |
124,403 | $549K |
| Dec 19, 2025 | Gibson Christopher Officer, Director |
40,000 | $180K |
| Dec 4, 2025 | Gibson Christopher Officer, Director |
40,000 | $185K |
| Dec 2, 2025 | Borgeson Blake Director |
220,000 | $961K |
| Nov 19, 2025 | Gibson Christopher Officer, Director |
40,000 | $166K |
Show the other 55 notices
From the Form 144 XML filed with the SEC, since Nov 19, 2025. The value is the seller's estimate on the notice. "Form 4 sales after" matches the seller's Form 4 sales in the 30 days after the notice, by name; Form 4s go back 180 days.
Sources
Regulation S-K Item 408 in the XBRL of each 10-Q and 10-K (since 2023); the Form 144 XML at the SEC.
Also
Insider trades: the Form 4s for the sales these plans led to.
Work with it
Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/RXRX/export.csv") into a cell.